Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13924000 | 1.00 | KDM4E (0.53) | KDM4EALDH1A1LMNAHSD17B10HTT | |
| SCHEMBL8237095 | 0.89 | KDM4E (0.53) | KDM4EALDH1A1LMNAHSD17B10HTT | |
| SCHEMBL8237099 | 0.89 | KDM4E (0.53) | KDM4EALDH1A1LMNAHSD17B10HTT | |
| SCHEMBL8245982 | 0.80 | KDM4E (0.46) | KDM4EALDH1A1HSD17B10HTTCASP1 | |
| SCHEMBL13924001 | 0.78 | KDM4E (0.48) | KDM4EALDH1A1LMNAHSD17B10HTT | |
| SCHEMBL8242657 | 0.78 | KDM4E (0.48) | KDM4EALDH1A1LMNAHSD17B10HTT | |
| SCHEMBL14517536 | 0.77 | KDM4E (0.42) | KDM4EALDH1A1LMNAHSD17B10HTT | |
| SCHEMBL6101444 | 0.75 | KDM4E (0.78) | KDM4EALDH1A1LMNAHSD17B10HTT | |
| SCHEMBL8277857 | 0.75 | KDM4E (0.80) | KDM4EALDH1A1LMNAHSD17B10HTT | |
| SCHEMBL8242662 | 0.75 | KDM4E (0.80) | KDM4EALDH1A1LMNAHSD17B10HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989464-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989464-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2011-08-02 | — | — | US | disclosed |
| EP-1966220-B1 | MGLUR1 ANATGONISTS AS THERAPEUTIC AGENTS | SCHERING CORP (US) | 2011-01-26 | — | — | EP | disclosed |
| EP-1765829-B1 | TRICYCLIC COMPOUNDS AND THEIR USE AS MGLUR1 ANTAGONISTS | SCHERING CORP (US) | 2010-07-07 | — | — | EP | disclosed |
| US-7598259-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598259-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090192178-A1 | mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION | 2009-07-30 | — | — | US | disclosed |
| US-20090192178-A1 | mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION | 2009-07-30 | — | — | US | disclosed |
| US-20090082336-A1 | mGluR1 Antagonists as Therapeutic Agents | SCHERING CORPORATION | 2009-03-26 | — | — | US | disclosed |
| US-20090082336-A1 | mGluR1 Antagonists as Therapeutic Agents | SCHERING CORPORATION | 2009-03-26 | — | — | US | disclosed |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | SCHERING CORPORATION | 2006-07-27 | — | — | US | disclosed |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | SCHERING CORPORATION | 2006-07-27 | — | — | US | disclosed |
| WO-2006002051-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS MGLUR1 ANTAGONISTS | SCHERING CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192178-A1 | mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS | GRM1, GRM4, GRIA1 | KDM4E 1129/4885ALDH1A1 1026/4885LMNA 4462/4885 |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | GRM1, GRM4, GRIA1 | KDM4E 1129/4885ALDH1A1 1026/4885LMNA 4462/4885 |
| US-20090082336-A1 | mGluR1 Antagonists as Therapeutic Agents | GRM1, GRM4, GRIA1 | KDM4E 1129/4885ALDH1A1 1026/4885LMNA 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.